Delaware, CRISPR and Cellicon Valley: A Special Event on February 6th

Bringing gene-editing technology from laboratory to bedside

Wilmington, DE, January 23, 2020 — As a leading biotech developer and center for pharma/life sciences research under the Greater Philadelphia ‘Cellicon Valley’ innovation hub, Delaware continues to play a leading role in the advancement of CRISPR technology.

The First State has the only gene-editing institute in the country embedded in a community cancer center, currently using CRISPR tech in lung cancer research. Delaware also can boast that the patent-pending computer code used to ‘translate’ the groundbreaking gene-editing technology was developed by a Newark Charter high school junior.

The state is a perfect testing ground because the population is representative of the general patient population across the county, a critical component of the development process. And the collaborative nature of our biotech industry allows for cross-pollination that would be more difficult elsewhere.Eric Kmiec, PH.D., Director, Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at ChristianaCare

“Delaware is the health laboratory of the country,” said Eric Kmiec, PH.D., Director, Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at ChristianaCare. “The state is a perfect testing ground because the population is representative of the general patient population across the county, a critical component of the development process. And the collaborative nature of our biotech industry allows for cross-pollination that would be more difficult elsewhere.”

Gene-Editing Technology Panel Discussion

Delaware Bio, a nonprofit trade organization with the mission of catalyzing growth in the state’s life-science industry, is presenting a panel discussion on gene editing that goes beyond CRISPR technology. To be held Thursday, February 6th from 1:30-5pm at the ChristianaCare John H. Ammon Medical Education Center, the event will provide an overview of the opportunities and challenges expected in bringing genome editing from the laboratory to the patient bedside.

Registration is required. To sign up, visit delawarebio.org. Last day to register is Thursday, January 30th.

We are delighted to bring together this talented panel to share their perspectives on the challenges of bringing genome editing from the laboratory to the bedside to educate and support the diverse population of gene and cell therapy companies in the greater Philadelphia regionHelen Stimson, CEO & President, Delaware Bio
Delaware Bio President Helen Stimson

”We are delighted to bring together this talented panel to share their perspectives on the challenges of bringing genome editing from the laboratory to the bedside to educate and support the diverse population of gene and cell therapy companies in the greater Philadelphia region,” said DelawareBio President Helen Stimson.

Formed in early 2006 as Delaware BioScience Association, Delaware Bio has brought together pharmaceutical and biotechnology firms, medical device manufacturers, agricultural biotech and chemical companies, research and testing companies, hospitals and medical institutions, and other organizations and related service companies, with the shared goal of expanding the state’s vibrant science economy.

 

Event Information

Attendees of the February 6th event will…
⦁ Hear from leading experts on the science behind genome editing and challenges in IP landscapes
⦁ Get an update on the latest genome editing discoveries and ChristianaCare’s CRISPR lung cancer research initiative
⦁ Learn what is happening at NIST to set industry standards, and about anticipated challenges from a public policy perspective
⦁ Gain a high-level overview on product development strategies to ensure plans are scientifically sound and meet regulatory expectations and clinical objectives.

Moderated by Maiken Scott, host of WHYY’s The Pulse, a national health and science radio show and podcast, panel members include Eric Kmiec, PH.D, Director, Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at ChristianaCare; Samantha Maragh, PH.D., Leader, Genome Editing Program, NIST (National Institute of Standards and Technology); Maritza McIntyre, PH.D., President, Advanced Therapies Partners, LLC; Robert Oakes, Esquire, Principal, Fish & Richardson, and Cartier Esham, Executive Vice President, Emerging Companies, of Biotechnology Innovation Organization (BIO).

For further information, contact Jamie Pedrick, Marketing Manager, Delaware BioScience Association at [email protected] or 302.635.0445.

CONTACT:

Jamie Pedrick
Marketing Manager
Delaware Bio
2110 Concord Pike | Wilmington | DE | 19803
www.delawarebio.org
[email protected]
(302) 635-0445

PRESS RELEASE GRACIOUSLY SPONSORED BY:

GET SOCIAL WITH US!  #DEBIO